AstraZeneca (AZN) AZD-9291 Data Highlights Blockbuster Potential

September 30, 2013 10:08 AM EDT Send to a Friend
Get Alerts AZN Hot Sheet
Price: $70.12 +1.11%

Rating Summary:
    6 Buy, 8 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade AZN Now!
Join SI Premium – FREE
Leerink Swann maintained a Market Perform rating on AstraZeneca (NYSE: AZN) with a modified price target of $51.00 (from $50.00). Analyst Seamus Fernandez believes impressive AZD-9291 data highlights blockbuster potential despite
competition.

"Impressive data for AZD-9291 in T790m + lung cancer patients presented at ESMO 2013 coupled with bullish commentary from the discussant and a MEDACorp KOL imply blockbuster potential for this class of agents (AZD-9291, CO1686)," said Fernandez. [Note: CO1686 in development by Clovis Oncology (NASDAQ: CLVS)]

"Given 7/12 partial responses in T790m + patients, excellent overall tolerability, and the high frequency (50-60%) of acquired EGFR-TKI (Roche's Tarceva, AZN's Iressa), we are adding $500M into our model for AZD-9291 despite potential competition from CO1686 given AZD-9291's excellent overall tolerability, what we expect will be rapid advancement into registrational Ph III trials, and an overall market front line and TKI-refractory market that could exceed $3B globally. We are growing increasingly intrigued by AZN's growing pool of assets in oncology & respiratory disease." added the analyst.

For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.

Shares of AstraZeneca closed at $51.77 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment